AbbVie (ABBV) Tops Q1 EPS by 4c, Raises Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Abbvie (ABBV) PT Lowered to $187 at Barclays
April 29, 2024 5:22 AM EDTBarclays analyst Carter Gould lowered the price target on Abbvie (NYSE: ABBV) to $187.00 (from $195.00) while maintaining a Overweight rating.
The analyst comments "Humira erosion and transient headwinds drive reframing of '25 EPS growth, though LT profile keeps us positively biased; lowering PT to $187."
... MoreAbbVie (ABBV) hikes 2024 earnings guidance as Q1 beat estimates, shares up
April 26, 2024 7:42 AM EDTAbbVie (NYSE: ABBV) shares rose 2.4% in premarket trading Friday after the company raised full-year guidance for adjusted earnings per share (EPS) as Q1 results beat expectations.
The pharmaceutical company reported earnings per share (EPS) of $2.31 for the fiscal Q1, exceeding the consensus estimate of $2.27.... More
